What does it take to make a natural killer?

Nature Reviews Immunology

Volumn 3, Issue 5, 2003, Pages 413-425

  Colucci, Francesco ^a   Caligiuri, Michael A ^b   Di Santo, James P ^a  

^a INSTITUT PASTEUR   (France)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 5;

ANIMAL CELL; CELL DIFFERENTIATION; CELL INTERACTION; CELL MATURATION; CYTOLYSIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LIFESPAN; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; ANIMAL; BIOLOGICAL MODEL; CELL LINEAGE; CELL MOTION; COMPARATIVE STUDY; CULTURE TECHNIQUE; IMMUNOLOGY; LEUKEMIA; NEOPLASM; PHYSIOLOGY;

ANIMALS; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL LINEAGE; CELL MOVEMENT; HEMATOPOIETIC STEM CELLS; HUMANS; INTERLEUKIN-15; KILLER CELLS, NATURAL; LEUKEMIA; MICE; MODELS, IMMUNOLOGICAL; NEOPLASMS;

EID: 0037711333     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1088     Document Type: Review

References (124)

1. Matsunaga, T. & Rahman, A. What brought the adaptive immune system to vertebrates? The jaw hypothesis and the seahorse. Immunol. Rev. 166, 177-186 (1998).
2. Medzhitov, R. & Janeway, C. Jr. Innate immune recognition: mechanisms and pathways. Immunol. Rev. 173, 89-97 (2000).
3. Colucci, F., Di Santo, J. P. & Leibson, P. J. Natural killer cell activation in mice and men: different triggers for similar weapons? Nature Immunol. 3, 807-813 (2002). A recent update on receptors, ligands and signalling molecules that regulate natural killer (NK)-cell activation.
4. Godin, I. & Cumano, A. The hare and the tortoise: an embryonic haematopoietic race. Nature Rev. Immunol. 2, 593-604 (2002). An excellent review of haematopoiesis with special emphasis on the comparison between formation of blood cells in the embryo and in the adult.
5. Seaman, W. E., Gindhart, T. D., Greenspan, J. S., Blackman, M. A. & Talal, N. Natural killer cells, bone, and the bone marrow: studies in estrogen-treated mice and in congenitally osteopetrotic (mi/mi) mice. J. Immunol. 122, 2541-2547 (1979).
6. 89strontium: normal target-binding cell numbers but inability to kill even after interferon administration. J. Immunol. 123, 1832-1838 (1979).
7. Herberman, R. B., Nunn, M. E., Holden, H. T. & Lavrin, D. H. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int. J. Cancer 16, 230-239 (1975).
8. Sirianni, M. C., Businco, L., Seminara, R. & Aiuti, F. Severe combined immunodeficiencies, primary T-cell defects and DiGeorge's syndrome in humans: characterization by monoclonal antibodies and natural killer cell activity. Clin. Immunol. Immunopathol. 28, 361-370 (1983).
9. Sihvola, M. & Hurme, M. The development of NK cell activity in thymectomized bone marrow chimeras. Immunology 53, 17-22 (1984).
10. Ramos, S. B., Garcia, A. B., Viana, S. R., Voltarelli, J. C. & Falcao, R. P. Phenotypic and functional evaluation of natural killer cells in thymectomized children. Clin. Immunol. Immunopathol. 81, 277-281 (1996).
11. Schwarz, R. E. & Hiserodt, J. C. Effects of splenectomy on the development of tumor-specific immunity. J. Surg. Res. 48, 448-453 (1990).
12. Passlick, B. et al. Posttraumatic splenectomy does not influence human peripheral blood mononuclear cell subsets. J. Clin. Lab. Immunol. 34, 157-161 (1991).
13. Phillips, J. H. et al. Ontogeny of human natural killer cells: fetal NK cells mediate cytolytic functions and express cytoplasmic CD3ε, δ proteins. J. Exp. Med. 175, 1055-1063 (1992).
14. + cells into T cells. J. Immunol. 159, 694-702 (1997).
15. + cells from human thymus precursors. J. Exp. Med. 174, 21-30 (1991).
16. Rodewald, H.-R. et al. A population of early fetal thymocytes expressing FcγR II/III contains precursors of T lymphocytes and natural killer cells. Cell 69, 139-146 (1992).
17. Ikawa, T., Kawamoto, H., Fujimoto, S. & Katsura, Y. Commitment of common T/natural killer (NK) progenitors to unipotent T and NK progenitors in the murine fetal thymus revealed by a single progenitor assay. J. Exp. Med. 190, 1617-1626 (1999).
18. Rosmaraki, E. E. et al. Identification of committed NK cell progenitors in adult murine bone marrow. Eur. J. Immunol. 31, 1900-1909 (2001). The first description of a committed NK-cell precursor in the bone marrow of adult mice. Its human counterpart has not been identified.
19. Spits, H. et al. Early stages in the development of human T. natural killer and thymic dendritic cells. Immunol. Rev. 165, 75-86 (1998).
20. - functionally immature human NK cell subset that differentiates in vitro in the presence of interleukin 12. J. Exp. Med. 184, 1845-1856 (1996).
21. -NK progenitor. Blood 83, 2594-2601 (1994).
22. + hematopoietic progenitor cells. Blood 85, 3538-3546 (1995).
23. + hematopoietic progenitor cells. Blood 87, 2632-2640 (1996).
24. - cells from multipotential murine bone marrow progenitors in a stroma-free culture: definition of cytokine requirements and developmental intermediates. J. Exp. Med. 186, 1609-1614 (1997). Reference 23 and 24 describe the minimal cytokine requirements (stromal-cell free) for generating NK cells in vitro. This process is remarkably similar in humans and mice.
25. Dokun, A. O. et al. Specific and nonspecific NK cell activation during virus infection. Nature Immunol. 2, 951-956 (2001).
26. Salazar-Mather, T. P., Orange, J. S. & Biron, C. A. Early murine cytomegalovirus (MCMV) infection induces liver natural killer (NK) cell inflammation and protection through macrophage inflammatory protein 1α (MIP-1α)-dependent pathways. J. Exp. Med. 187, 1-14 (1998).
27. Smyth, M. J. et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191, 661-668 (2000).
28. Akashi, K., Traver, D., Miyamoto, T. & Weissman, I. L. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 404, 193-197 (2000).
29. Kondo, M., Weissman, I. L. & Akashi, K. Identification of clonogenic common lymphoid progenitors in mouse bone marrow. Cell 91, 661-672 (1997).
30. Igarashi, H., Gregory, S. C., Yokota, T., Sakaguchi, N. & Kincade, P. W. Transcription from the RAG1 locus marks the earliest lymphocyte progenitors in bone marrow. Immunity 17, 117-130 (2002).
31. Sivori, S. et al. Early expression of triggering receptors and regulatory role of 2B4 in human natural killer cell precursors undergoing in vitro differentiation. Proc. Natl Acad. Sci. USA 99, 4526-4531 (2002).
32. + human natural killer cell progenitor that responds to interleukin-15. Blood 92, 3647-3657 (1998).
33. Lyman, S. D. & Jacobsen, S. E. c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood 91, 1101-1134 (1998).
34. Colucci, F. & Di Santo, J. P. The receptor tyrosine kinase c-kit provides a critical signal for survival, expansion, and maturation of mouse natural killer cells. Blood 95, 984-991 (2000).
35. Waskow, C., Paul, S., Haller, C., Gassmann, M. & Rodewald, H. Viable c-Kit(W/W) mutants reveal pivotal role for c-kit in the maintenance of lymphopoiesis. Immunity 17, 277-288 (2002).
36. Sitnicka, E. et al. Key role of flt3 ligand in regulation of the common lymphoid progenitor but not in maintenance of the hematopoietic stem cell pool. Immunity 17, 463-472 (2002).
37. Mackarehtschian, K. et al. Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity 3, 147-161 (1995).
38. McKenna, H. J. et al. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 95, 3489-3497 (2000).
39. Spritz, R. A. Molecular basis of human piebaldism. J. Invest. Dermatol. 103, S137-S140 (1994).
40. Billia, F., Barbara, M., McEwen, J., Trevisan, M. & Iscove, N. N. Resolution of pluripotential intermediates in murine hematopoietic differentiation by global complementary DNA amplification from single cells: confirmation of assignments by expression profiling of cytokine receptor transcripts. Blood 97, 2257-2268 (2001).
41. Warren, L. A. & Rothenberg, E. V. Regulatory coding of lymphoid lineage choice by hematopoietic transcription factors. Curr. Opin. Immunol. 15, 166-175 (2003).
42. Wang, J. H. et al. Selective defects in the development of the fetal and adult lymphoid system in mice with an Ikaros null mutation. Immunity 5, 537-549 (1996).
43. + T cells. Blood 99, 513-519 (2002).
44. Nichogiannopoulou, A., Trevisan, M., Neben, S., Friedrich, C. & Georgopoulos, K. Defects in hemopoietic stem cell activity in Ikaros mutant mice. J. Exp. Med. 190, 1201-1214 (1999).
45. Borles, J. C. et al. Increased T-cell apoptosis and terminal B-cell differentiation induced by inactivation of the Ets-1 proto-oncogene. Nature 377, 635-638 (1995).
46. Barton, K. et al. The Ets-1 transcription factor is required for the development of natural killer cells in mice. Immunity 9, 555-563 (1998).
47. Scott, E. W., Simon, M. C., Anastasi, J. & Singh, H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science 265, 1573-1577 (1994).
48. Colucci, F. et al. Differential requirement for the transcription factor PU.1 in the generation of natural killer cells versus B and T cells. Blood 97, 2625-2632 (2001).
49. DeKoter, R. P., Lee, H. J. & Singh, H. PU.1 regulates expression of the interleukin-7 receptor in lymphoid progenitors. Immunity 16, 297-309 (2002).
50. Radtke, F. et al. Notch1 deficiency dissociates the intrathymic development of dendritic cells and T cells. J. Exp. Med. 191, 1085-1094 (2000).
51. Schaniel, C., Bruno, L., Melchers, F. & Rolink, A. G. Multiple hematopoietic cell lineages develop in vivo from transplanted Pax5-deficient pre-BI-cell clones. Blood 99, 472-478 (2002).
52. Engel, I. & Murre, C. The function of E- and Id proteins in lymphocyte development. Nature Rev. Immunol. 1, 193-199 (2001).
53. Heemskerk, M. H. et al. Inhibition of T cell and promotion of natural killer cell development by the dominant negative helix loop helix factor Id3. J. Exp. Med. 186, 1597-1602 (1997).
54. + stem cells into predendritic cell (pre-DC)2 but not into pre-DC1. Evidence for a lymphoid origin of pre-DC2. J. Exp. Med. 192, 1775-1784 (2000).
55. Yokota, Y. et al. Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2. Nature 397, 702-726 (1999). The first example of a transcription factor that selectively affects NK-cell development.
56. Ikawa, T., Fujimoto, S. Kawamoto, H., Katsura, Y. & Yokota, Y. Commitment to natural killer cells requires the helix-loop-helix inhibitor Id2. Proc. Natl Acad. Sci. USA 98, 5164-5169 (2001).
57. Zamai, L. et al. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J. Exp. Med. 188, 2375-2380 (1998).
58. + multipotent marrow progenitor cells. J. Immunol. 163, 2648-2656 (1999).
59. Roth, C., Carlyle, J. R., Takizawa, H. & Raulet, D. H. Clonal acquisition of inhibitory Ly49 receptors on developing NK cells is successively restricted and regulated by stromal class I MHC. Immunity 13, 143-153 (2000).
60. Miller, J. S. & McCullar, V. Human natural killer cells with polyclonal lectin and immunoglobulin-like receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2. Blood 98, 705-713 (2001).
61. Kim, S. et al. In vivo developmental stages in murine natural killer cell maturation. Nature Immunol. 3, 523-528 (2002).
62. Iizuka, K. et al. Requirement for membrane lymphotoxin in natural killer cell development. Proc. Natl Acad. Sci. USA 96, 6336-6340 (1999).
63. Wu, Q. et al. Signal via lymphotoxin-β R on bone marrow stromal cells is required for an early checkpoint of NK cell development. J. Immunol. 166, 1684-1689 (2001).
64. Ogasawara, K. et al. Requirement for IRF-1 in the microenvironment supporting development of natural killer cells. Nature 391, 700-703 (1998).
65. + T) cells, natural killer cells, and intestinal intraepithelial T cells. J. Exp. Med. 187, 967-972 (1998).
66. + progenitors via cell surface IL-15. J. Immunol. 168, 4326-4332 (2002).
67. + severe combined immunodeficiency. Nature Genet. 20, 394-397 (1998).
68. DiSanto, J. P. et al. Absence of interleukin 2 production in a severe combined immunodeficiency disease syndrome with T cells. J. Exp. Med. 171, 1697-1704 (1991).
69. Kundig, T. M. et al. Immune responses in interleukin-2-deficient mice. Science 262, 1059-1061 (1993).
70. Sharfe, N., Dadi, H. K., Shahar, M. & Roifman, C. M. Human immune disorder arising from mutation of the α chain of the interleukin-2 receptor. Proc. Natl Acad. Sci. USA 94, 3168-3171 (1997).
71. Kennedy, M. K. et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 191, 771-780 (2000).
72. Lodolce, J. P. et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 9, 669-676 (1998). References 71 and 72 illustrate the essential and non-redundant role of IL-15 and its receptor in mouse NK-cell development. A defect in the human IL-15 receptor results in NK-cell deficiency, as described in reference 48.
73. Suzuki, H., Duncan, G. S., Takimoto, H. & Mak, T. W. Abnormal development of intestinal intraepithelial lymphocytes and peripheral natural killer cells in mice lacking the IL-2 receptor β chain. J. Exp. Med. 185, 499-505 (1997).
74. Di Santo, J. P., Müller, W., Guy-Grand, D., Fischer, A. & Rajewsky, K. Lymphoid development in mice with a targeted deletion of the interleukin-2 receptor γ chain. Proc. Natl Acad. Sci. USA 92, 377-381 (1995).
75. Noguchi, M. et al. Interleukin-2 receptor γ chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 73, 147-157 (1993).
76. Gilmour, K. C. et al. Defective expression of the interleukin-2/interleukin-15 receptor β subunit leads to a natural killer cell-deficient form of severe combined immunodeficiency. Blood 98, 877-879 (2001).
77. Lodolce, J. P., Burkett, P. R., Boone, D. L., Chien, M. & Ma, A. T cell-independent interleukin 15Rα signals are required for bystander proliferation. J. Exp. Med. 194, 1187-1194 (2001).
78. Pereno, R. et al. IL-15/IL-15Rα intracellular trafficking in human cells and protection from apoptosis. Ann. NY Acad. Sci. 876, 236-245 (1999).
79. Dubois, S., Mariner, J., Waldmann, T. A. & Tagaya, Y. IL-15Rα recycles and presents IL-15 in trans to neighboring cells. Immunity 17, 537-547 (2002). This paper proposes a new model for the function of IL-15.
80. Giri, J. G. et al. Identification and cloning of a novel IL-15 binding protein that is structurally related to the α chain of the IL-2 receptor. EMBO J. 14, 3654-3663 (1995).
81. Cerwenka, A. & Lanier, L. L. Ligands for natural killer cell receptors: redundancy or specificity. Immunol. Rev. 181, 158-169 (2001).
82. Raulet, D. H., Vance, R. E. & McMahon, C. W. Regulation of the natural killer cell receptor repertoire. Annu. Rev. Immunol. 19, 291-330 (2001).
83. Braud, V. M. et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391, 795-799 (1998).
84. Vance, R. E., Kraft, J. R., Altman, J. D., Jensen, P. E. & Raulet, D. H. Mouse CD94/NKG2A is a natural killer cell receptor for the nonclassical major histocompatibility complex (MHC) class I molecule Qa-1(b). J. Exp. Med. 188, 1841-1848 (1998).
85. Smith, H. R. et al. Nonstochastic coexpression of activation receptors on murine natural killer cells. J. Exp. Med. 191, 1341-1354 (2000).
86. Ljunggren, H. G. & Karre, K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol. Today 11, 237-244 (1990).
87. Lanier, L. L., Le, A. M., Civin, C. I., Loken, M. R. & Phillips, J. H. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J. Immunol. 136, 4480-4486 (1986).
88. Smyth, M. J., Hayakawa, Y., Takeda, K. & Yagita, H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nature Rev. Cancer 2, 850-861 (2002). An excellent review on recent advances in our understanding of the role of NK cells in cancer and the possibility of using them in therapy.
89. Parrish-Novak, J. et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408, 57-63 (2000).
90. Kasaian, M. T. et al. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 16, 559-569 (2002).
91. Orange, J. S. et al. Deficient natural killer cell cytotoxicity in patients with IKK-γ/NEMO mutations. J. Clin. Invest. 109, 1501-1509 (2002).
92. Zhou, J., Zhang, J., Lichtenheld, M. G. & Meadows, G. G. A role for NF-κB activation in perforin expression of NK cells upon IL-2 receptor signaling. J. Immunol. 169, 1319-1325 (2002).
93. Kaisho, T. et al. Impairment of natural killer cytotoxic activity and interferon-γ production in CCAAT/enhancer binding protein γ-deficient mice. J. Exp. Med. 190, 1573-1582 (1999).
94. Lohoff, M. et al. Deficiency in the transcription factor interferon regulatory factor (IRF)-2 leads to severely compromised development of natural killer and T helper type 1 cells. J. Exp. Med. 192, 325-336 (2000).
95. Ito, A. et al. Inhibitory effect on natural killer activity of microphthalmia transcription factor encoded by the mutant mi allele of mice. Blood 97, 2075-2083 (2001).
96. Lacorazza, H. D. et al. The ETS protein MEF plays a critical role in perforin gene expression and the development of natural killer and NK-T cells. Immunity 17, 437-449 (2002).
97. bright subset. Blood 97, 3146-3151 (2001). This paper provides the first clear evidence that human NK cells can be divided in two distinct subsets on the basis of expression of cell-surface markers and division of labour. Whether this applies to mouse NK cells is not known.
98. Benlagha, K., Kyin, T., Beavis, A., Teyton, L. & Bendelac, A. A thymic precursor into the NK T cell lineage. Science 296, 553-555 (2002).
99. Loza, M. J. & Perussia, B. Final steps of natural killer cell maturation: a model for type 1-type 2 differentiation? Nature Immunol. 2, 917-924 (2001).
100. Loza, M. J., Peters, S. P., Zangrilli, J. G. & Perussia, B. Distinction between IL-13 and IFN-γ natural killer cells and regulation of their pool size by IL-4. Eur. J. Immunol. 32, 413-423 (2002).
101. Peritt, D. et al. Differentiation of human NK cells into NK1 and NK2 subsets. J. Immunol. 161, 5821-5824 (1998).
102. Hoshino, T., Wiltrout, R. H. & Young, H. A. IL-18 is a potent coinducer of IL-13 in NK and T cells: a new potential role for IL-18 in modulating the immune response. J. Immunol. 162, 5070-5077 (1999).
103. Lauwerys, B. R., Garot, N., Renauld, J. C. & Houssiau, F. A. Cytokine production and killer activity of NK/T-NK cells derived with IL-2, IL-15, or the combination of IL-12 and IL-18. J. Immunol. 165, 1847-1853 (2000).
104. Ranson, T. et al. IL-15 is an essential mediator of peripheral NK cell homeostasis. Blood (in the press)
105. Cooper, M. A. et al. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood 100, 3633-3638 (2002).
106. dim natural killer cell subsets. J. Immunol. 161, 400-408 (1998).
107. bright natural killer cells are present in human lymph nodes and are activated by T cell derived IL-2: a potential new link between adaptive and innate immunity. Blood 101, 3052-3057 (2003).
108. Moffet-King, A. Natural killer cells and pregnancy. Nature Rev. Immunol. 2, 656-663 (2002).
109. Croy, B. A., Chantakru, S., Esadeg, S., Ashkar, A. A. & Wei, Q. Decidual natural killer cells: key regulators of placental development. J. Reprod. Immunol. 57, 151-168 (2002).
110. Cooper, M. A., Fehniger, T. A. & Caligiuri, M. A. The biology of human natural killer-cell subsets. Trends Immunol. 22, 633-640 (2001).
111. Farag, S. S., Fehniger, T. A., Ruggeri, L., Velardi, A. & Caligiuri, M. A. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 100, 1935-1947 (2002).
112. Caligiuri, M. A. et al. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J. Clin. Invest. 91, 123-132 (1993).
113. Fehniger, T. A. et al. Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy. J. Clin. Invest. 106, 117-124 (2000).
114. Clynes, R. A., Towers, T. L., Presta, L. G. & Ravetch, J. V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nature Med. 6, 443-446 (2000).
115. Meropol, N. J. et al. Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing. Cancer Immunol. Immunother. 46, 318-326 (1998).
116. Ruggeri, L. et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295, 2097-2100 (2002). In a mismatched transplantation setting, NK cells prevented relapse of acute myeloid leukaemia. Importantly, these alloreactive NK cells did not cause graft-versus-host disease, mediated graft-versus-leukaemia effects and allowed better engraftment of donor cells.
117. Minagawa, M. et al. Enforced expression of Bcl-2 restores the number of NK cells, but does not rescue the impaired development of NKT cells or intraepithelial lymphocytes, in IL-2/IL-15 receptor β-chain-deficient mice. J. Immunol. 169, 4153-4160 (2002).
118. Piguet, P. F., Grau, G., Irle, C. & Vassalli, P. Administration of recombinant interleukin 2 to mice enhances production of hemopoietic and natural killer cells. Eur. J. Immunol. 16, 1257-1261 (1986).
119. Nakajima, H. et al. The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients. J. Immunol. 168, 643-650 (2002).
120. Gilliland, D. G. Molecular genetics of human leukemias: new insights into therapy. Semin. Haematol. 39, 6-11 (2002).
121. Forbes, L. V. et al. An activating mutation in the transmembrane domain of the granulocyte colony-stimulating factor receptor in patients with acute myeloid leukemia. Oncogene 21, 5981-5989 (2002).
122. Hongyo, T. et al. Specific c-kit mutations in sinonasal natural killer/T-cell lymphoma in China and Japan. Cancer Res. 60, 2345-2347 (2000).
123. + T cells. J. Exp. Med. 193, 219-231 (2001).
124. Marks-Konczalik, J. et al. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc. Natl Acad. Sci. USA 97, 11445-11450 (2000).